快要 飞的 《药股》 讨论区

葉芬

Stocks to Watch - 10/19/09 - Stock Market Ideas


CEL-SCI Corp. (CVM) - CVM remains one of the hottest stocks on Wall Street right now. The stock is trading back over all three major moving averages. I like CVM as long as it can continue to close at or over $1.60. Pullbacks to the 10 day moving average ( currently $1.45 ) should be a great buying opportunity for a trade. The next major resistance level is located at $1.70 & $1.80

葉芬

Latest PR:

CEL-SCI Presents Data at American College of Rheumatology Conference Which Suggests that CEL-2000 Has Potential to Slow

CEL-SCI Presents Data at American College of Rheumatology Conference Which Suggests that CEL-2000 Has
Potential to Slow Damage Caused by Rheumatoid Arthritis --Statistically Significant Results Support Approach
Of Company's H1N1 Platform

Mon Oct 19 09:45:00 2009
EDT
VIENNA, Va., Oct 19, 2009 /PRNewswire-FirstCall via COMTEX News Network/ --
CEL-SCI Corporation (NYSE Amex: CVM) announced today the presentation of new
rheumatoid arthritis data at the American College of Rheumatology's annual meeting
in Philadelphia, PA.  The data, presented by Dr. Daniel Zimmerman in conjunction
with the Company's collaborators from Washington Biotech, Northeastern Ohio Universities
College of Medicine and BolderBiopath, indicate that CEL-SCI's rheumatoid arthritis
treatment vaccine CEL-2000 acts to prevent or retard the permanent tissue damage
caused by rheumatoid arthritis in animals.  These statistically significant results
were demonstrated by the measurement of four different parameters, suggesting that
CEL-2000 appears to block the immune response that causes the autoimmunity which
leads to rheumatoid arthritis.  The long term results obtained with fewer doses
of CEL-2000 vaccine were comparable or better than those seen with Enbrel(R), a
leading treatment for people with rheumatoid arthritis.
Geert Kersten, Chief Executive Officer of CEL-SCI said, "These results were
achieved through a reduction of the inflammatory response that attacks the patient's
joints.  The goal for our new H1N1 therapy for H1N1 hospitalized patients is not
dissimilar.  Many of these patients die from the excessive inflammatory response.
We feel that this new data is encouraging both for this rheumatoid arthritis vaccine
as well as supportive of our H1N1 treatment."
In these studies, mice were injected with collagen to induce the autoimmune
disease.  Therapy with Enbrel or CEL-2000 was initiated and continued for 28 days
after the initiation of a significant, uniform, and measurable level of arthritic
disease in groups of mice.  CEL-2000 was administered only twice, but Enbrel was
administered every other day for the first 28 days. The extent of disease, as indicated
by deformation of foot joints (Arthritic Index (AI) score), of untreated, and CEL-2000
and Enbrel treated groups, was compared.  In another study CEL-2000 was administered
5 times over a 70 day period and the animals were monitored for another 20 days
for a total study period of 90 days.   In each case, CEL-2000 treatment proved effective
at blocking the progression of disease with statistically significant reduction
in AI score compared to the appropriate controls and was safe and well tolerated
without any adverse effects.  The protection mediated by CEL-2000 treatment was
also demonstrated histologically by significant reductions in   1) inflammation,
2) cartilage destruction 3) bone resorption, and 4) pannus membrane formation in
the synovial space compared to untreated controls.
The CEL-2000 treatment appeared to change the course of the immune response
in the diseased and treated animals by limiting the development of a destructive
Th17 and tumor necrosis factor alpha (TNF-alpha) directed autoimmune response.  
Analysis of serum levels of 21 cytokines/chemokines indicated reductions in the
characteristic cytokine markers of rheumatoid arthritis, TNF-alpha and IL-17, and
also IL-6, and MCP-1.  A number of cytokine changes were also seen with Enbrel treatment,
but to a lesser degree.
CEL-2000 may also offer a number of potential advantages over existing rheumatoid
arthritis treatments, such as Enbrel.  Data collected in the animal studies conducted
with CEL-2000 demonstrated that CEL-2000 is an effective treatment against arthritis
even with the administration of fewer treatments.  CEL-2000 is also potentially
a more disease-type specific therapy, should be significantly less expensive and
finally, CEL-2000 could also be useful for patients who are not able to take or
who may be unresponsive to existing anti-arthritis therapies.
Rheumatoid arthritis treatments comprise a $13 billion market.  Enbrel, a
leading rheumatoid arthritis treatment sold by Amgen and Wyeth, reported US sales
in 2007 of about $3.2 billion.  Enbrel is a soluble recombinant protein of a human
TNF-alpha receptor linked to human IgG Fc.  In some cases, human or humanized monoclonal
antibodies specific against TNF-alpha have also been used for therapy in rheumatoid
arthritis.  These therapies remove or inactivate TNF-alpha, a natural human cytokine
required in many immune functions for normal defenses.
CEL-SCI's rheumatoid arthritis vaccine CEL-2000 was discovered as part of
work with the Company's ongoing research and development activities with its L.E.A.P.S.(TM)
(Ligand Epitope Antigen Presentation System) technology.  L.E.A.P.S. is a novel
T-cell modulation platform technology that enables CEL-SCI to design and synthesize
proprietary immunogens. Any disease for which an antigenic sequence has been identified,
such as infectious, parasitic, malignant or autoimmune diseases and allergies, are
potential therapeutic or preventive sites for the application of L.E.A.P.S. technology.
The concept behind the L.E.A.P.S. technology is to directly mimic cell-cell
interactions and activate immune cells with synthetic peptides. The L.E.A.P.S. constructs
containing the antigenic disease epitope linked to a immune-cell binding ligand
(ICBL) can be manufactured by peptide synthesis or by covalently linking the two
peptides. Depending upon the type of L.E.A.P.S. construct and ICBL used, CEL-SCI
is able to direct the outcome of the immune response towards the development of
T-cell function with primarily effector T-cell functions (T Lymphocyte; helper/effector
T lymphocyte, type 1 or 2 [Th1 or Th2], cytotoxic [Tc] or suppressor [Ts]). Therefore,
it would appear that the L.E.A.P.S. construct represents a chimeric peptide with
bi-functional behavior.
Additional details on the presentation are available at http://acr.confex.com/acr/2009/webprogram/Paper10996.html.
CEL-SCI Corporation is developing products that empower immune defenses.
Its lead product is Multikine(R) which is being readied for a global Phase III trial
in advanced primary head and neck cancer.  CEL-SCI is also developing a treatment
for hospitalized H1N1 patients using its L.E.A.P.S. technology platform and expects
to soon finish the validation of its state-of-the-art facility in Maryland.
When used in this report, the words "intends," "believes," "anticipated"
and "expects" and similar expressions are intended to identify forward-looking statements.
Such statements are subject to risks and uncertainties which could cause actual
results to differ materially from those projected. Factors that could cause or contribute
to such differences include, lack of regulatory clearance to proceed with clinical
trials, an inability to duplicate the clinical results demonstrated in clinical
studies that have been completed or that are initiated in the future, timely development
of any potential products that can be shown to be safe and effective, unwillingness
of regulatory authorities to engage in further regulatory dialogue, receiving necessary
regulatory approvals, difficulties in manufacturing any of the Company's potential
products, inability to raise the necessary capital, and the risk factors set forth
from time to time in CEL-SCI Corporation's SEC filings, including but not limited
to its report on Form 10- K/A for the year ended September 30, 2008. The Company
undertakes no obligation to publicly release the result of any revision to these
forward-looking statements which may be made to reflect the events or circumstances
after the date hereof or to reflect the occurrence of unanticipated events.
For more information, please visit www.cel-sci.com
SOURCE  CEL-SCI Corporation
http://www.cel-sci.com
Copyright (C) 2009 PR Newswire. All rights reserved

CVM,

VA-CEL-SCI-arthritis, BIOTECHNOLOGY, BUSINESS, csta+stories, FINANCE, financenews, financenews+select,
HEALTHCARE, hedge+funds, prn, PUBCO+SELECT, PUBLIC+COMPANIES, WALL+STREET,

This content is for use with eSignal products by authorized persons only. Any reference; link, frame,
or other use of this material without the explicit permission of eSignal is prohibited.

weiherd

原帖由 葉芬 于 19-10-2009 09:52 PM 发表
Latest PR:

CEL-SCI Presents Data at American College of Rheumatology Conference Which Suggests that CEL-2000 Has Potential to Slow

CEL-SCI Presents Data at American College of Rheumatology Confe ...

刚才开市跳水，现在收复失地了，期待中。。。

葉芬

原帖由 weiherd 于 19-10-2009 10:06 PM 发表


刚才开市跳水，现在收复失地了，期待中。。。

你也有買？

今晚是有大戶拉她的價錢下。。。
今晚的價錢應該是1.60左右。。。

[ 本帖最后由 葉芬 于 19-10-2009 10:10 PM 编辑 ]

weiherd

原帖由 葉芬 于 19-10-2009 10:08 PM 发表




你也有買？

今晚是有大戶拉她的價錢下。。。
今晚的價錢應該是1.60左右。。。

买在1.3， 收到月尾看。。

葉芬

原帖由 weiherd 于 19-10-2009 10:13 PM 发表


买在1.3， 收到月尾看。。

1.30 很好的價錢。

要不是大戶玩她，她的價錢早就過2元了。。

葉芬

原帖由 雨若情 于 19-10-2009 11:29 PM 发表
cvm今天又下了。。。
哎哟也！早知道不要贪心。
有早知 某黑衣

因為是關于CVM的，所以我帖回這裏。希望你不介意。

像今天的走勢，也是個賺錢的機會。
是看你自己能不能抓的那機會吧了。。

我的是先賣後買。 1次。
又1次是先買後賣。 一共2次。

[ 本帖最后由 葉芬 于 19-10-2009 11:42 PM 编辑 ]

miku

原帖由 葉芬 于 19-10-2009 11:40 PM 发表



因為是關于CVM的，所以我帖回這裏。希望你不介意。

像今天的走勢，也是個賺錢的機會。
是看你自己能不能抓的那機會吧了。。

我的是先賣後買。 1次。
又1次是先買後賣。 一共2次。

你就好啦。。今天钱在别的股的。。看到cvm1.3没有买！！

雨若情

这个我也知道 可是我这里只有p1.线路不好。
之前我的sppi跑不了 亏了少少哦。
一次就怕咯。所以 我都是limit卖。
我要搬家~~我要搬家~~

葉芬

分享。。。

http://biomedreports.com/article ... e-applications.html



http://www.earthtimes.org/articles/show/cel-sci-presents-data-at-american,1003848.shtml

葉芬

原帖由 miku 于 19-10-2009 11:57 PM 发表


你就好啦。。今天钱在别的股的。。看到cvm1.3没有买！！

  大家一樣leh。。 你今天沒買CVM，買別的股也一樣有收獲。

葉芬

原帖由 雨若情 于 20-10-2009 12:31 AM 发表
这个我也知道 可是我这里只有p1.线路不好。
之前我的sppi跑不了 亏了少少哦。
一次就怕咯。所以 我都是limit卖。
我要搬家~~我要搬家~~

P1 是什么來的？

韦一笑

原帖由 葉芬 于 20-10-2009 03:53 AM 发表



P1 是什么來的？

是用来上网的咯。数度蛮快的。。好像不用电话线plug in 就可运作。

葉芬

原帖由 韦一笑 于 20-10-2009 08:06 AM 发表



是用来上网的咯。数度蛮快的。。好像不用电话线plug in 就可运作。

是 Mobile Broadband 嗎？

葉芬

分享：（有買CVM的網友們，這是給你們的一顆定心丸。）


http://vfcsstockhouse.blogspot.c ... ate-for-monday.html


Monday, October 19, 2009
VFC's Cel Sci (CVM) Update for Monday
CVM: Shares of Cel Sci traded with continued volatility on Monday, after the company announced positive results for CEL-2000 (based on the company's LEAPS technology) in the treatment of Rheumatoid arthritis at the American College of Rheumatology Conference in Philadelphia on Sunday. It was also noted at the conference by Cel-Sci that the potential treatment indications for LEAPS are plentiful, in addition to the company's current investigative treatment for the swine flu.

Another negative (and expected) article by TheStreet.com on Monday morning may have contributed to some mid-day selling, but I believe that many investors were expecting bigger news to hit the wires and bailed when that news did not materialize, then looked for a chance to get back in for a lower price later in the day.

That being said, it's worth picking up a few shares on any dips into the $1.30s, in my opinion, because of the short to mid term potential for significant news to be released; including an update on the FDA validation of the Baltimore manufacturing facility, which would (I assume) be followed by a potential commencement of the much-anticipated Multikine Phase III trial.

Any indication from either the FDA or Cel Sci that LEAPS for the treatment of the swine flu is a 'go' would significantly pushe the stock to higher levels, in my opinion.

It's also become painfully apparent (and boring) that Adam Feuerstein, TheStreet.com's biotech blogger, has a personal vendetta or hidden agenda against Cel-Sci. Feuerstein's blog posts continue to report on anything but valid developments regarding the Cel-Sci pipeline and the small investor would be better off looking to another source for a place to begin the DD, rather than reading OP-ED pieces that misrepresent or ignore the facts.

The bottom line is this, Feuerstein is looking for 'clicks' to his articles, just like any other blogger, and if he's got to incite negativity from his readers to get paid - or support another agenda - then there's nothing we can do about that except ignore it.

I, personally, find it morally reprehensible to go to the extremes that Adam does in an attempt to discredit a company that is working on a breakthrough treatment for a big killer like head and neck cancer, but that's just me. Time will tell whether or not the small investor did the right thing by investing in Cel Sci, and time will tell if Multikine is the life saver that, thus far it's proven to be. But in the meantime, the developments of the company look good and there's plenty of resources out there for the small investor to gather the real and unabated facts.

I'm also inclined to believe that if Feuerstein spent more time researching stocks than he does trying to bring a beef with Garza at BioMedReports, he might find good stocks like CVM while they're trading for twenty cents and tip his readers off to them rather than wait until a stock has a huge run and then find a reason to bash it.

As for CVM, it's already a huge percentage winner this year, and I continue to believe that things are just getting started for Cel Sci. I'll continue to add on the dips.

Disclosure: VFC is long CVM.

葉芬

http://finance.google.com/group/ ... ad/b36998126d1fd35b


http://finance.google.com/group/google.finance.87959/browse_thread/thread/1e2397ffbf104698?hl=en#




Google Discussions Board 裏的 Mc M 的分析做的不錯。
多看他寫的CVM。。。

[ 本帖最后由 葉芬 于 20-10-2009 09:38 AM 编辑 ]

葉芬

http://www.emailwire.com/release ... nvestorSoupcom.html


Trading Review for CEL-SCI Corp. issued by InvestorSoup.com
The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
(EMAILWIRE.COM, October 20, 2009 ) DALLAS, Texas - InvestorSoup.com.com announces an investment report featuring CEL-SCI Corp. (AMEX: CVM).

The investment report on CEL-SCI Corp. (AMEX: CVM) should be of particular interest to other biopharmaceutical companies: Gilead Sciences Inc. (Nasdaq: GILD), Genzyme Corp. (Nasdaq: GENZ) and Life Technologies Corp. (Nasdaq: LIFE).

It is available at: http://www.investorsoup.com/lp/CVM

Get our alerts BEFORE the rest of the market. Follow us on Twitter: www.twitter.com/investorsoup

CEL-SCI Corp. (CVM) is engaged in the development of a product called Multikine for the treatment of cancer. It simulates the activities of a healthy person's immune system, which battles cancer every day. Multikine is multi-targeted; it is the cancer immunotherapy that kills cancer cells in a targeted fashion and activates the general immune system to destroy the cancer. Multikine is a type of immunotherapy in that it is a comprehensive immunotherapy, incorporating both active and passive immune activity. The Company also develops CEL-1000, which is derived from a pre-clinical technology called Ligand Epitope Antigen Presentation System for protection for animals against avian flu, herpes, malaria and more.

In the report, the analyst notes:

“The Company has two partners who have agreed to participate in and pay for part of the phase III clinical trial for Multikine. However in light of the current capital market environment, the Company believes it is prudent not to start the phase III clinical trial until it has firm commitments in the form of partnerships and/or money raised for a substantial amount of cash to support the phase III clinical trial. Additionally, the Company obtained new financing of $5,845,241 in June of 2009, net of financing costs of $339,329. The Company is currently working toward a transaction that will finance its phase III clinical trial of Multikine.

“CVM is currently moving forward as fast as is possible with its proposed dendritic H1N1 treatment for hospitalized H1N1 patients, while proceeding with due caution and taking all necessary steps to meet regulatory requirements.”

雨若情

要看地点 好的时候很好 。
奶奶的 下雨大风就sot了

葉芬

原帖由 雨若情 于 20-10-2009 08:10 PM 发表
要看地点 好的时候很好 。
奶奶的 下雨大风就sot了

有這樣的東西？？


看來Streamyx暫時還是最穩的了。。

韦一笑

原帖由 葉芬 于 20-10-2009 09:01 AM 发表



是 Mobile Broadband 嗎？

嗯，听说旧款的比较好一点，只不过比较大架。。